Citations

Showing 10 of 108104 citations.

SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.
Paterson, Alexander , Lew, Danika L., Hayes, Daniel F. , Schubert, Mark, Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Livingston, Robert B., Gralow, Julie R. , Barlow, William E. , Stopeck, Alison , Hershman, Dawn L. , Clemons, Mark , Ingle, James N. , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 558-558

10.1200/jco.2014.32.15_suppl.558 Get It

Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.
Spector, Neil L., Mano, Max S. , Canon, Jean-Luc, Gómez, Henry , El‐Hariry, Iman , Vukovic, Vojislav, Sheldon, Emily H, Perez, Edith A. , Cameron, David , Cortés, Javier , Canon, Jean-Luc Re , Hickish, Tamas , Vahdat, Linda T. , Kim, Sung-Bae , Awada, Ahmad

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS665-TPS665

10.1200/jco.2014.32.15_suppl.tps665 Get It

Efficacy of adjuvant trastuzumab (T) compared with no T for patients (pts) with HER2-positive breast cancer and tumors ≤ 2cm: A meta-analysis of the randomized trastuzumab trials.
O’Sullivan, Ciara C. , Bradbury, Ian , Perez, Edith A. , Rastogi, Priya , Spielmann, M., Costantino, Joseph P., Zardavas, Dimitrios, Piccart, Martine , Zujewski, JoAnne, Holmes, Eileen , Gelber, Richard D. , Azambuja, Evandro de , Joensuu, Heikki , Ballman, Karla V. , Delaloge, Suzette , Zujewski, Jo Anne

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 508-508

10.1200/jco.2014.32.15_suppl.508 Get It

Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC).
Chapman, Judy‐Anne W., Burnell, Margot J., Levine, Mark N. , O’Brien, Patti, Han, Lei , Albain, Kathy S. , Perez, Edith A. , Vandenberg, Theodore A. , Chalchal, Haji , Sawhney, Ravinder, Shepherd, Lois E. , Lohmann, Ana Elisa , Tsvetkova, Elena V. , Pritchard, Kathleen I. , Gelmon, Karen A. , Rugo, Hope S. , Goodwin, Pamela J.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 504-504

10.1200/jco.2014.32.15_suppl.504 Get It

Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).
Liebman, Mira, Brien, William, Parulekar, Wendy R. , Shepherd, Lois E. , Ligibel, Jennifer A. , Rastogi, Priya , Hobday, Timothy J. , Thompson, Alastair M. , Whelan, Timothy J. , Mukherjee, Som D., Chalchal, Haji , Bernstein, Vanessa , Gelmon, Karen A. , Hershman, Dawn L. , Mayer, Ingrid A. , Lemieux, Julie , Pritchard, Kathleen I. , Stambolic, Vuk , Chen, Bingshu E. , Goodwin, Pamela J. , Whelan, Timothy J

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 542-542

10.1200/jco.2014.32.15_suppl.542 Get It

Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
Wagle, Nikhil , Richardson, Andrea L. , Forero‐Torres, Andres , Hobday, Timothy J. , Dees, Elizabeth Claire , Nanda, Rita , Rimawi, Mothaffar F. , Barry, William T., Gabriel, Stacey B., Garraway, Levi A. , Krop, Ian E. , Rimawi, Mothaffar , Lin, Nancy U. , Leshchiner, Ignaty , Mayer, Ingrid A. , Wolff, Antonio C. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2014.32.15_suppl.536 Get It

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Tan, Antoinette R. , Wong, Serena, Warren, Robert, Eng‐Wong, Jennifer , Liu, Minetta C. , Zelnak, Amelia, Shih, Weichung, Ganesan, Shridar , Grana, Generosa , Toppmeyer, Deborah , Lin, Yong , Isaacs, Claudine

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 531-531

10.1200/jco.2014.32.15_suppl.531 Get It

Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety
Ritchie, Brianne M., Barreto, Jason N. , Frazee, Erin N. , Crow, Stacy A., Dierkhising, Ross , Jannetto, Paul J. , Tosh, Pritish K. , Dierkhising, Ross A, Razonable, Raymund R.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 3, 2019 | Volume: 63 | Issue: 3 | Pages: No page available

10.1128/aac.01855-18 | PMID 30602515 Get It

The clinical utility of ganciclovir therapeutic drug monitoring (TDM) is unknown. We retrospectively analyzed adult patients treated for cytomegalovirus (CMV) infection with ganciclovir with TDM between 2005 and 2015.
A Moldy Application of MALDI: MALDI-ToF Mass Spectrometry for Fungal Identification
Patel, Robin , Patel, Robin

Mayo Clinic

Journal of Fungi | January 3, 2019 | Volume: 5 | Issue: 1 | Pages: 4

10.3390/jof5010004 | PMID 30609833 Get It

As a result of its being inexpensive, easy to perform, fast and accurate, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-ToF MS) is quickly becoming the standard means of bacterial identification from cultures in clinical microbiology laboratories. Its adoption for routine identification of yeasts and even dimorphic and filamentous fungi in cultures, while slower, is now being realized, with many of the same benefits as have been recognized on the bacterial side. In this review, the use of MALDI-ToF MS for identification of yeasts, and dimorphic and filamentous fungi grown in culture will be reviewed, with strengths and limitations addressed.